ITI-3000

Phase 1Small molecule

IImmunomic Therapeutics, Inc.

ITI-3000 is one of 38 small molecule programs targeting Merkel Cell Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Merkel Cell CarcinomaActive, not recruiting

Merkel Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Merkel Cell Carcinoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

3 2

Dostarlimab

Incyte

Phase 2

3 3

Yervoy

Bristol-Myers Squibb

Phase 2

2 4

Cabometyx

Bristol-Myers Squibb

Phase 2

1 5

Lenvima

Eisai

Phase 2

1 6

Taxol

Teva

Phase 2

1 7

Bavencio

EMD Serono

Phase 2

9 8

Abraxane

Bristol-Myers Squibb

Phase 2

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 10

Lanreotide Acetate

AAlbireo, an Ipsen Company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Merkel Cell Carcinoma1 trial

Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)

Completed·IImmunomic Therapeutics, Inc.·Phase 1·NCT05422781·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ITI-3000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ITI-3000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ITI-3000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immunomic Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IImmunomic Therapeutics, Inc.

ITI-3000

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Merkel Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News